



# World Journal of Pharmacy and Biotechnology

ISSN: 2349-9087 | www.pharmaresearchlibrary.com/wjpb

W. J. Pharm. Biotech., 2017, 4(1): 01-03

DOI: <https://doi.org/10.30904/j.wjpb.2017.3387>



## A Case Report on Ceftriaxone Induced Hypersensitivity Reaction (Urticaria)

Pradeep Battula<sup>1</sup>, S. Afreen\*<sup>2</sup>, A. Surekha<sup>2</sup>, V. Vijaya Prasad<sup>2</sup>

<sup>1</sup>Assistant professor, Department of pharmacy practice, CES College of Pharmacy, N.H-7, Chinnatekur, Kurnool, Andhra Pradesh, India.

<sup>2</sup>Pharm-D student Department of pharmacy practice, CES College of Pharmacy, N.H-7, Chinnatekur, Kurnool, Andhra Pradesh, India.

### ABSTRACT

Ceftriaxone is a third generation cephalosporin's group of broad spectrum antibiotic. It is active against gram positive and gram negative organism and is commonly used for respiratory tract infections, urinary tract infections and meningitis. Diagnosis of anaphylaxis is clinically based and usually straight forward. Usually ceftriaxone is well tolerated and serious adverse effect like anaphylaxis is rare. Hypersensitivity reaction with ceftriaxone is unusual but is potentially life threatening it is rapidly occurring reaction hence called immediate hypersensitivity reaction. Whenever the patient exposes to certain drugs (penicillin, cephalosoprins and aspirins) production of IgE E anti bodies occurs that fix to mast cells then again reexposure to same drug causes antigen – antibody reaction on mast cell surface then release of inflammatory mediators like histamine, 5HT, PG'S, LT'S, PAF occurs. These mediators cause the hypotension bronchospasm angioedema urticaria rhinitis and anaphylactic shock. Management of hypersensitivity reactions include Inj. Adrenaline 0.3-0.5ml, intramuscularly, Inj. Hydrocortisone 100-200mg intravenously, Inj. Pheneramine maleate 45mg intravenously.

**Keywords:** ceftriaxone, 3<sup>rd</sup> generation cephalosporin's, hypersensitivity reactions

### ARTICLE INFO

#### Corresponding Author

S. Afreen  
Department of Pharmaceutics,  
CES College of Pharmacy,,  
N.H-7, Chinnatekur, Kurnool, A.P, India.

#### Article History

Received : 31 Mar 2017  
Revised : 29 April 2017  
Accepted : 05 May 2017  
Published : 29 June 2017

**Copyright© 2017** The Contribution will be made Open Access under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC) (<http://creativecommons.org/licenses/by-nc/4.0>) which permits use, distribution and reproduction in any medium, provided that the Contribution is properly cited and is not used for commercial purposes.

**Citation:** S. Afreen, et al. A Case Report on Ceftriaxone Induced Hypersensitivity Reaction (Urticaria). *W. J. Pharm. Biotech.*, 2017, 4(1): 01-03.

### Contents

1. Introduction.....	01
2. Case Report.....	02
3. ADR Assessment.....	02
4. Conclusion.....	02
5. References.....	02

### 1. Introduction

Ceftriaxone is a third generation cephalosporin's group of broad spectrum antibiotics. It is active against gram positive and gram negative organism and is commonly used for respiratory tract infections, urinary tract infections meningitis, etc. It mainly acts by inhibiting last step of cell wall synthesis. Anaphylaxis is an acute life threatening reaction usually but not always mediated by immunologic mechanisms that result from sudden systemic release of mediators from mast cells and basophils. Other mediator

cascade includes non-mastcell-derived mediators responsible for many symptoms occurring in anaphylactic reaction. [1, 2] Anaphylaxis often produces signs and symptoms within minutes to an offending stimulus but some reactions may develop later (>30 mins after exposure). Biphasic reactions which occur 1-72 hours after the initial attack have also been reported. [3] Drug allergies are classified into IgE mediated (type I hypersensitivity) and non IgE mediated. IgE mediated reactions include urticaria, angioedema, bronchospasms, skin eruptions, anaphylactic

reactions. Non IgE mediated includes SJS, haemolytic anemia, interstitial nephritis, serum sickness, etc. Diagnosis of anaphylaxis is clinically based and usually straight forward. Usually ceftriaxone is well tolerated and the serious adverse effect like anaphylaxis is rare. There are inadequate results that say that cephalosporins are causing this kind of hypersensitivity. Incidence of ceftriaxone related hypersensitivity reaction is between 2.7% to 3.3%.



**Figure 1:** Ceftriaxone induced hypersensitivity reaction (Urticaria)

## 2. Case Report

A 42yrs female patient was presented in the ward of general medicine with the chief complaints of fever, headache, body pains, giddiness, vomiting, and neck stiffness since 4 days. On the day of admission she was kept on treatment based on her complaints. On day 2 she was suspected with viral meningitis thus the treatment for meningitis was started with acyclovir and mannitol. She had developed hypersensitivity reactions (urticaria) around the nose as shown in the figure. For which she was prescribed with dexamethasone and then ceftriaxone was withdrawn. The

previous day she was started treatment with ceftriaxone to reduce hospital acquired infections. After 24hrs of treatment she has developed the urticaria around her nose.

**Treatment outcome and follow up:** She was treated with Mannitol 20% 8<sup>th</sup> hourly, Dexamethasone 100mg and Acyclovir 100mg then the ADR was reduced after 2 days of discontinuation of drug.

## 3. ADR Assessment

After collection of all the subjective and objective data it was suspected that the current treatment with the drug ceftriaxone is responsible for the occurrence of this reaction. After checking all the ADR profiles of prescribed drugs it was confirmed that ceftriaxone has a most probable relation in causing this reaction. ADR assessment is done by using scales like narinjo scale and WHO-UMC scales and those scales confirms this reaction is a probable type as shown in table 1.

### Discussion

Anaphylaxis is an acute, life threatening reaction which is often associated with dyspnoea, angioedema and hypotension, resulting from the release of preformed, newly sensitized bioactive mediators from mast cells and basophils. Anaphylaxis is a medical emergency and usually requires active and prompt resuscitative measures such as airway management, supplemental oxygen, adrenaline, intravenous fluid boluses along with steroids and antihistamines as adjunctive therapy. A patient who has an allergic reaction to a specific cephalosporin probably should not receive that cephalosporin group again.[5] Cross reaction between cephalosporins do occur. Thus it is really difficult to predict anaphylaxis to cephalosporin and strict vigilance and preparedness is mandatory.

**Table 1. Causality assessment of suspected ADR**

S.No	Suspected drug	ADR	Narinjo scale	WHO-UMC
1	Ceftriaxone (Gemtrex) 1g, BD	Hypersensitivity reaction (Urticaria)	Probable	Probable

**Table 2. Severity, Predictability, Preventability**

ADR	Suspected drug	Severity	Predictability	Preventability
Ceftriaxone induced hypersensitivity reaction	Ceftriaxone	Moderate (level 4)	Predictable (Type B)	Probably preventable

## 4. Conclusion

Even there is a lower increase in possibility of causing anaphylaxis but when it occurs in a patient there is a role of health care providers to be aware of this complication which can occur even after first dose and should be vigilant on recognizing anaphylaxis and provide prompt treatment accordingly.

## 5. Reference

[1] Helbling A, Hurni T, Muller UR, Pichler WJ. Incidence of anaphylaxis with circulatory symptoms: A study over 3 year period comprising 9,40,000 inhabitants of the swiss canton Bern. Clin Exp Allergy. 2004;34:285-90.

[2] Liberman P, Nicklas RA, Oppenheimer J, Kemp SF, Lang DM, Bernstein DI, et al. The diagnosis and Management of anaphylactic practice parameter: 2010 update. J Allergy Clin Immunol. 2010; 126:477-80.e1-42.

[3] Liberman P. Biphasic anaphylactic reactions. Ann Allergy Asthma Immunol. 2005; 95:217-26.

[4] [http://www.micromedexsolutions.com/micromedex2/librarian/CS/8F2323/ND\\_PR/evidencexpert/ND\\_P/evidencexpert/DUPLICATIONSHIELDSYN C/93EC09/ND\\_PG/evidencexpert/ND\\_B/evidencexpert/ND\\_AppProduct/evidencexpert/ND\\_T/evidencexpert/PFActionId/evidencexpert.DoIntegratedSearch?SearchTerm=ceftriaxone&UserSearchTerm](http://www.micromedexsolutions.com/micromedex2/librarian/CS/8F2323/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYN C/93EC09/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.DoIntegratedSearch?SearchTerm=ceftriaxone&UserSearchTerm)

=ceftriaxone&SearchFilter=filterNone&navitem=searchall#. Accessed on 22/2/17

- [5] Saxon A, Beall GN, Rohr AS, Adelman DC. Immediate hypersensitivity reaction to beta lactam antibiotics. *Ann Intern Med* 1987, 107(2): 204-15.